Global Hemp Group Inc (GHG-WT.CN)
| Previous Close | 0.0100 |
| Open | 0.0000 |
| Bid | 0.0100 x N/A |
| Ask | 0.0150 x N/A |
| Day's Range | 0.0100 - 0.0100 |
| 52 Week Range | 0.0050 - 0.0100 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Global Hemp Group Announces Execution of Exclusive Licensing Agreement for the Intellectual Property of Apollon Formularies PLC Covering the United States, Canada, and Mexico
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that further to the Company's announcement of January 11, 2023 regarding the execution of the binding LOI with Apollon Formularies Plc - (AQSE: APOL) ("Apollon"), the Parties have now executed an exclusive licensing agreement (the "License Agreement") dated January 19, 2023 covering the licensing of the right to Apollon'
- Newsfile
Global Hemp Group Announces Execution of Binding LOI with Apollon Formularies PLC
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that it has executed a binding Letter of Intent with Apollon Formularies Plc - (AQSE: APOL) ("Apollon") (the "LOI"), a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compou
